Lisata Therapeutics Collaborates with Kuva Labs to Advance Non-Invasive, High-Precision Cancer Diagnostics
Shots:
- Lisata Therapeutics and Kuva Labs have entered into a global collaboration and licensing agreement to advance non-invasive, high-precision cancer diagnostics
- As per the agreement, Kuva secures rights to Lisata's certepetide (iRGD peptide) to be used with its NanoMark platform, forming advanced MR imaging agents for safe & non-invasive diagnosis of solid tumors
- Kuva will cover all NanoMark research, development & commercialization costs, while Lisata will provide certepetide. The deal includes an upfront, milestone payments, and royalties for Lisata
Ref: Lisata Therapeutics | Image: Lisata Therapeutics
Related News:- Lisata Therapeutics and the University of Cincinnati Enters into Sponsored Agreement for Certepetide to Treat Endometriosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
